Kyat3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| KYAT3 Protein |
|---|
| Protein Name | Kynurenine Aminotransferase 3 |
| Gene | KYAT3 |
| UniProt | Q9H3R9 |
| Molecular Weight | 45 kDa |
| Subcellular Localization | Cytoplasm, Mitochondria |
| Protein Family | Aminotransferase family (fold class I) |
KYAT3 (Kynurenine Aminotransferase 3), also known as KAT3 or CCBL2 (Cysteine Conjugate-Beta Lyase 2), is a pyridoxal phosphate-dependent aminotransferase involved in the kynurenine pathway of tryptophan degradation. This pathway produces neuroactive metabolites including kynurenic acid and quinolinic acid, which have opposing effects on NMDA receptor signaling. KYAT3 is implicated in epilepsy, Alzheimer's disease, and Parkinson's disease[1].
KYAT3 contains key structural features:
- PLP-binding Domain: Pyridoxal phosphate cofactor for transamination
- Dimerization Interface: Forms functional homodimers
- Active Site Pocket: Substrate-specific binding for kynurenine and cysteine conjugates
KYAT3 participates in multiple metabolic pathways:
- Kynurenine Pathway: Catalyzes transamination of kynurenine to kynurenic acid (KYNA)
- Cysteine Metabolism: Acts as a cysteine S-conjugate beta-lyase
- Neuroprotection: Produces KYNA, an endogenous NMDA receptor antagonist
- Quinolinic Acid Regulation: Indirectly influences QA levels through pathway flux
KYAT3 functions through:
- Transamination: Kynurenine + alpha-ketoglutarate → KYNA + glutamate
- Cysteine Conjugate Beta-Lysis: Cleaves cysteine S-conjugates to produce pyruvate, ammonia, and thiols
- PLP-dependent Catalysis: Uses vitamin B6 as a cofactor
- Substrate Competition: Competes with KAT1/KAT2 for kynurenine
KYAT3 is critical in epilepsy pathophysiology:
- KYNA Deficiency: Reduced KYAT3 leads to lower KYNA, increasing excitotoxicity
- Seizure-Induced Changes: Acute seizures alter KYAT3 expression
- Therapeutic Target: KYNA-enhancing compounds are being explored[2]
KYAT3 plays complex roles in AD:
- KYNA/QA Balance: Shift toward quinolinic acid promotes neurodegeneration
- Microglial Activation: Alters neuroinflammatory responses
- Amyloid Effects: Aβ may suppress KYAT3 expression
In PD, KYAT3 dysfunction contributes to:
- Dopaminergic Neuron Vulnerability: Altered kynurenine metabolism
- Neuroinflammation: Increased quinolinic acid toxicity
- Therapeutic Modulation: KYAT3 modulators being investigated
Targeting KYAT3-related pathways:
- KYNA Agonists: Enhance KYNA production for neuroprotection
- Enzyme Modulators: Increase KYAT3 activity
- Pathway Inhibitors: Block downstream quinolinic acid production
- Dietary Interventions: Tryptophan modulation
Key areas of investigation:
- Understanding KYAT3 regulation in different brain cell types
- Developing selective KYAT3 modulators
- Biomarkers for kynurenine pathway activity
- Links between KYAT3 and other neurodegenerative processes
The study of Kyat3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Guidetti P, et al. (2007). Kynurenine pathway enzymes in neurodegeneration. Neurotoxicology. PMID:17336322
- Potter MC, et al. (2010). Kynurenic acid and epilepsy. Epilepsy Res. PMID:20133191
- Schwarcz R, et al. (2012). The kynurenine pathway and the brain. Neuropsychopharmacology. PMID:22048464
- Haroutunian V, et al. (2015). Kynurenine pathway in Alzheimer's disease. J Neural Transm. PMID:26250503
- Zádori D, et al. (2019). Kynurenines in Parkinson's disease. J Neural Transm. PMID:31325492
KYAT3 (Kynurenine Aminotransferase 3), also known as CAT3, shows specific expression:
- High expression: Cerebral cortex, hippocampus, basal ganglia
- Moderate expression: Cerebellum, thalamus, brainstem
- Cell type specificity: Primarily expressed in neurons, some astrocytic expression
- Transcriptionally induced by inflammatory cytokines (IFN-γ, TNF-α)
- Epigenetic regulation via DNA methylation
- Activity modulated by vitamin B6 availability
KYAT3 catalyzes the transamination of kynurenine pathway intermediates:
- Primary substrate: 3-hydroxyanthranilic acid (3-HANA)
- Secondary substrates: Kynurenine, quinolinic acid
- Cofactor: Pyridoxal 5'-phosphate (PLP/vitamin B6)
- Product: 3-hydroxyanthranilic acid to quinolinic acid
- Irreversible step in kynurenine pathway
- Regulates flux toward NAD+ biosynthesis
- Controls levels of neuroactive metabolites
In the brain, KYAT3:
- Modulates extracellular kynurenic acid levels
- Influences glutamatergic signaling via NMDA receptors
- Affects oxidative stress response
- Altered KYAT3 expression in AD brain
- Increased quinolinic acid neurotoxicity
- Potential therapeutic target for neuroprotection
- Dysregulated kynurenine pathway in PD
- KYAT3 as modulatory target
- Connection to mitochondrial dysfunction
- Altered kynurenine metabolism in seizure disorders
- KYAT3 as anticonvulsant target
| Approach |
Strategy |
Status |
| KYAT3 inhibitors |
Reduce toxic metabolites |
Preclinical |
| Vitamin B6 supplementation |
Enhance PLP availability |
Clinical trials |
| Kynurenic acid analogs |
Modulate NMDA signaling |
Research |
- Kyat3-/- mice show altered kynurenine metabolism
- Increased susceptibility to neurotoxicity
- Behavioral phenotypes under investigation
- KYAT3 overexpression: Neuroprotective effects
- Useful for drug screening
- Development of selective KYAT3 inhibitors
- Biomarker potential of KYAT3 activity
- Gene therapy approaches
- Understanding cross-talk with neuroinflammation